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FXYD5: Na+/K+-ATPase Regulator in
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Department of Biological Chemistry, Weizmann Institute of Science, Rehovot, Israel
FXYD5 (Dysadherin, RIC) is a single span type I membrane protein that plays multiple
roles in regulation of cellular functions. It is expressed in a variety of epithelial tissues and
acts as an auxiliary subunit of the Na+/K+-ATPase. During the past decade, a correlation
between enhanced expression of FXYD5 and tumor progression has been established for
various tumor types. In this review, current knowledge on FXYD5 is discussed, including
experimental data on the functional effects of FXYD5 on the Na+/K+-ATPase. FXYD5
modulates cellular junctions, influences chemokine production, and affects cell adhesion.
The accumulated data may provide a basis for understanding the molecular mechanisms
underlying FXYD5 mediated phenotypes.
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FXYD5 (Dysadherin, RIC) is a type I membrane protein, that belongs to FXYD family. In
mammalian cells this family of proteins consists of seven members (FXYD1-7) that share the
conserved F-X-Y-D motif in the trans-membrane domain. All family members are known to
interact with Na+/K+-ATPase and affect its kinetic properties in a tissue-specific manner (for
a review see Garty and Karlish, 2006). FXYD5 was identified as a cell surface molecule by a
monoclonal antibody that was developed to selectively recognize cancerous but not normal cells.
Due to its effect of reducing cell–cell adhesion in transfected PLC/PRF/5 liver cancer cells the
protein was termed dysadherin (Ino et al., 2002). Dysadherin and FXYD5 are synonyms for the
same protein, consisting of 178 amino acid residues.
FXYD5 is expressed in a variety of cell types. Its role has been well characterized in epithelial
tissues, probably due to the high abundance of FXYD5 in these cells and its up-regulation in
several carcinomas, which originated from epithelial cells. FXYD5 was particularly abundant in
intestine, spleen, lung, and kidney, and to much less extent in muscle tissues (Lubarski et al., 2005,
2007). Additional studies also recognized FXYD5 in endothelial cells and lymphocytes (Ino et al.,
2002). The physiological significance of FXYD5 expression in the lymphatic system remains to be
determined. The muscle tissues are a composite of a variety of cell types, and there is no indication
yet, if FXYD5 expression in this tissue is myocyte specific. For instance, FXYD5 expression could
be compartmentalized to endothelial cells, which are a part of the vascular supply to muscle bundle.
FXYD5: STRUCTURE, MOLECULAR WEIGHT VARIABILITY, AND
POST TRANSLATIONAL MODIFICATIONS
Unlike other family members, FXYD5 has an atypically long extracellular domain >140 amino
acids, including a cleavable signal peptide. FXYD5 has a short intracellular C-terminal segment of
only 15 amino acids (Lubarski et al., 2005). The calculated molecular mass of FXYD5 is ∼20 kDa,
and without signal peptide the predicted molecular mass is∼17 kDa. In a variety of normal mouse
epithelial tissue, a ∼24 kDa polypeptide was reported to bind to two different antibodies raised
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independently against the synthetic C-terminal peptide and
the truncated N-terminal domain (Lubarski et al., 2005, 2007).
A similar molecular mass was also found for HA-tagged
recombinant protein translated from the mouse FXYD5 cDNA
in several cell lines (Lubarski et al., 2011, 2014). In agreement,
Miller and Davis demonstrated that mature human Flag-tagged
FXYD5 cDNA transfected into HEK 293 or LA4 cells produced
protein that migrated as an indistinct band of ∼35 kDa,
and in mouse as a 25 kDa band (Miller and Davis, 2008a).
However, in several cancerous cell lines antibodies recognized
natively expressed FXYD5 of different molecular sizes, ranging
between 50 and 55 kDa (Ino et al., 2002; Shimamura et al.,
2004). The N-terminal domain, has a high abundance of Ser,
Thr, and Pro residues, that were reported to be extensively
O-glycosylated, an observation that could explain the variability
in the apparent molecular weight of the protein (Ino et al.,
2002; Tsuiji et al., 2003). Nevertheless, other explanations
cannot be excluded. For example, detergent-resistant multimers
in membrane preparations of cells expressing a FXYD5-Flag
construct have been observed (Miller and Davis, 2008b). A
similar phenomenon has also been reported for other FXYD
proteins (Garty and Karlish, 2006; Wypijewski et al., 2013). Thus,
the general conclusion is that some O-glycosylation is always
present, since the migration size of native and expressed FXYD5
in all of the reported expression systems is consistently higher
than the predicted molecular weight, and the presence of sugar
moieties was demonstrated by lectin binding to the 24 kDa
protein (Lubarski et al., 2011). Thus, the 50–55 kDa molecular
species could be either a dimeric form of FXYD5 or a highly
glycosylated species that is prevalent mainly in cancerous cells.
In either case this issue deserves further investigation.
As discussed below, whereas the FXYD5 trans-membrane
segment acts as a kinetic modulator of Na+/K+-ATPase activity,
neither the N nor C extra-membrane segments of FXYD5
have been characterized in terms of possible functional effects
(Lubarski et al., 2007). The intracellular region of FXYD5
is considerably shorter than that of the other FXYD family
members and consists of only 15 amino acids. Interestingly, our
observations have shown that any alterations to the C-terminus,
such as deletion or tagging, results in failure of the protein
to express at the surface, suggesting that the C-terminus is
essential for correct folding or plasma membrane trafficking
or both functions. In spite of its short length the C-terminus
is known to undergo various post-translational modifications.
For example, Ser163, a conserved residue in all FXYD proteins,
has been suggested as a target for kinase-mediated regulation
of cell motility in an in vitro model of airway epithelia. The
authors concluded that phosphorylation at Ser163 regulates the
FXYD5/Na+/K+-ATPase interaction and that this interaction
modulates cell migration across a wound in airway epithelial cells
(Miller and Davis, 2008b).
FXYD5 has two cysteines in its intracellular region,
Cys168 and Cys170. Neither residue is exclusive for FXYD5
and both are located in equivalent positions throughout
the FXYD family. Although the equivalent cysteines in all
FXYD proteins are predicted to undergo palmitoylation, this
modification has been demonstrated experimentally only
for FXYD1 and FXYD5 (Tulloch et al., 2011; Martin et al.,
2012). Palmitoylation of FXYD1 was reported to be promoted
by PKC phosphorylation and to be required for inhibition
of the Na+/K+-ATPase activity (Tulloch et al., 2011). The
functional role of FXYD5 palmitoylation, if any, has not yet been
characterized. Nevertheless, since all FXYD members have at
least one conserved cysteine residue, palmitoylation may be a
general means of regulating the pump.
At least one splice variant has been identified for FXYD5
with a non-canonical GT/CC splice site (Lubarski et al., 2007).
Due to elimination of the original stop codon this splice variant
creates a longer transcript encoding 10 additional residues at the
C-terminus. Splice variants have also been reported for FXYD2
and FXYD3 (Kuster et al., 2000; Bibert et al., 2006). In both cases,
differential expression of the two variants was observed, and in
the case of FXYD3 different functional effects were also noted
(Bibert et al., 2006). The functional effect of FXYD5 splice variant
has not yet been analyzed.Table 1 summarizes the published data
of all FXYD5 modifications and mutations.
FUNCTIONAL INTERACTION OF FXYD5
WITH NA+/K+-ATPase
The specific interaction of FXYD5 with Na+/K+-ATPase was
demonstrated by co-immunoprecipitation in several expression
systems (Lubarski et al., 2005, 2007, 2011; Miller and Davis,
2008b). Similar to FXYD1 (Crambert et al., 2002), but unlike
FXYD4 and FXYD2 (Garty et al., 2002), association between
FXYD5 and the Na+/K+-ATPase was found efficient also in the
absence of Rb+/ouabain that preserve the native pump structure.
The stability of the αβ/FXYD5 complex in detergent solubilized
membranes and its high efficiency of co-immunoprecipitation
are determined by its trans-membrane domain, as demonstrated
by structure-function studies of FXYD5/FXYD4 chimeras
expressed in Xenopus oocytes (Lubarski et al., 2007). A
series of experiments, using point mutations, identified three
trans-membrane residues as particularly important for the
FXYD5/Na+/K+-ATPase interaction (Lubarski et al., 2007).
All three residues, Ala150, Ile160, and Leu161, are common to
all FXYD proteins, except FXYD4, and their significance for
association with the pump were described in earlier studies
(Lindzen et al., 2003; Li et al., 2004, 2005). A residue unique
to FXYD5, Arg145, is located at the membrane- extracellular
interface. Mutation of Arg145 to Gly (Arg145Gly), a residue
located at the equivalent position in most of the FXYD
family members, significantly increases the stability of the
FXYD5/Na+/K+-ATPase complex, as demonstrated by co-
immunoprecipitation experiments in HEK293 cells (Lubarski
et al., 2014). Due to the location of Arg145 at the membrane-
extracellular interface, the charge may have a major effect on the
position of FXYD5 within the plasma membrane.
One of the well characterized functional effects of FXYD5 is to
increase the pump activity (Vmax), measured either as ouabain-
blockable and K+-induced outward current, or as ouabain-
inhibitable 86Rb+ uptake. Co-expression of FXYD5 together with
the Na+/K+-ATPase in Xenopus laevis oocytes produces a more
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TABLE 1 | Summary of all published FXYD5 modifications and mutations.
Residues Location Modification Function Expression system References
1–21 N-terminus Signal peptide Plasma membrane targeting Xenopus oocytes Lubarski et al., 2005
22–145 N-terminus O-Glycosylation Up-regulated in cancer? PLC/PRF/5 Tsuiji et al., 2003
S163 C-terminus Phosphorylation Reduce association with Na+/K+-ATPase MDCK Miller and Davis,
2008b
C168, C170 C-terminus Palmitoylation Not tested T-cells Martin et al., 2012
179AYRVINMKES188 C-terminus Splice variant Not tested Dendritic cells Lubarski et al., 2007
A150, I160,L161 Transmembrane Mutation to G,M,A Reduce association with Na+/K+-ATPase Xenopus oocytes,
HEK293
Lubarski et al., 2007
R145 N-terminus, membrane
interphase
Mutation to G Increase association with Na+/K+-ATPase HEK293 Lubarski et al., 2014
than two-fold increase in the Vmax, without affecting the K0.5
for external K+ (Lubarski et al., 2005, 2007). In a separate study
using Madin-Darby canine kidney cells (MDCK), transfected
with FXYD5, the effect on Vmax was also demonstrated. In
addition, FXYD5 was shown to elevate the apparent affinity for
Na+ about two-fold, and decrease the apparent affinity for K+ by
60% (Miller and Davis, 2008a).
FXYD5-FXYD4 chimeras were used to study the structure-
function relations of different domains, measured by Rb86
uptake in Xenopus oocytes. These indicated that the FXYD5
trans-membrane segment is involved in the effect to increase
the pumping rate. Other parameters were not tested in
these experiments (Lubarski et al., 2007). Since the plasma
membrane expression of Na+/K+-ATPase, as quantified by
surface biotinylation, was not altered by FXYD5 expression, it
was concluded that FXYD5 elevates the turnover rate of the pump
(Lubarski et al., 2011).
The effects of FXYD5 on kinetic parameters of the
Na+/K+-ATPase are small, about two-fold, similar to those
reported for other FXYD proteins (Lubarski et al., 2005;
Garty and Karlish, 2006). However, they are likely to be
physiologically significant. The physiological role of the
kinetic effect of FXYD5 can be proposed on the basis of
its observed localization in normal tissue and on the basis
of phenotypic analysis of differential FXYD5 expression
under pathophysiological conditions. Interestingly, in kidney
the FXYD5 cellular expression pattern correlates with low
abundance of Na+/K+-ATPase. FXYD5 is expressed in cortical
collecting duct intercalated cells, which have almost undetectable
levels of the pump (Lubarski et al., 2005). Therefore, in
principle, a FXYD5-mediated increase in Vmax could serve
as a homeostatic mechanism that acts to moderate or restore
increased intracellular Na+ or decreased intracellular K+ ion
concentrations, without altering the number of pumps in
the cell. FXYD5 was found to be up-regulated during several
pathological events. Patients with spinal cord injury (SCI)
exhibited down-regulation of Na+/K+-ATPase, while FXYD5
expression was significantly increased (Boon et al., 2012).
In alveolar epithelial cells, during hypoxia, up-regulation of
FXYD5 was demonstrated, while several studies reported down
regulation in Na+/K+-ATPase, at the transcriptional level and a
decrease in the number of pumps at the basolateral membrane
(Planès et al., 1996; Clerici and Matthay, 2000; Wodopia et al.,
2000; Dada et al., 2003; Igwe et al., 2009). Up-regulation in
FXYD5 under these conditions may serve as a compensatory
mechanism to overcome the decrease in Na+/K+-ATPase unit
numbers, by increasing the pumping rate. A significant increase
in FXYD5 was found also in the lungs and nasal epithelium
of cystic fibrosis (CF) mice, at the level of both protein and
mRNA, and this up-regulation was directly correlated with loss
of Cystic fibrosis transmembrane conductance regulator (CFTR)
function (Miller and Davis, 2008a). Increased FXYD5 expression
observed in CF airway epithelia may contribute to the increased
Na+/K+-ATPase activity, which in turn may add to the greater
sodium reabsorption seen in CF. The regulatory mechanism of
FXYD5 increase under these pathological conditions is unknown
yet. Nevertheless, FXYD5 up-regulation was reported following
addition of pro-inflammatory cytokines TNFα or IL-1β (Miller
and Davis, 2008a). Since inflammation is a common outcome of
the above disorders it is a logical starting point in the evaluation
of pathways regulating FXYD5 expression.
While structural interaction between FXYD proteins and the
pump have been partially resolved by the crystal structures
(Kanai et al., 2013), the mechanistic details of FXYD5 functional
effects are still to be determined. It is certain, however, that the
kinetic effects detected in vitro are not the only outcome of the
FXYD5/Na+/K+-ATPase association as discussed below.
FXYD5 EXPRESSION IS UP-REGULATED
IN VARIOUS HUMAN TUMORS
FXYD5 has been identified as a cancer-associated protein. In a
number of clinical studies it was shown that there is a statistically
significant correlation between the FXYD5 abundance and the
progression of malignancies, accompanied by poor outcome of
patients with various cancers (for a review see Nam et al., 2007).
Initial studies showed that FXYD5 overexpression was correlated
with reduced cell–cell adhesiveness, giving rise to the name
“dysadherin” (Ino et al., 2002). In support of this concept, it was
found that the mouse FXYD5 gene was induced in NIH 3T3
fibroblasts, transformed by a variety of oncogenes, including E2a-
Pbx1, v-Ras, Neu, and v-Src (Fu and Kamps, 1997). Hence, clues
to the basis of this FXYD5mechanism of action is of high interest.
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Some evidence has suggested the link of FXYD5 to known
cancer promoting signaling pathways. In some cancer cell lines
and tumors FXYD5 overexpression has been correlated with
down-regulation of E-cadherin (Nakanishi et al., 2004; Batistatou
et al., 2005; Kyzas et al., 2006; Sato et al., 2013). It has
long been recognized that E-cadherin, acting as the cell–cell
adhesion receptor, has an important role in suppression of tumor
progression (Schipper et al., 1991; Oka et al., 1993; Umbas et al.,
1994). Therefore, it was proposed that FXYD5 might promote
metastasis by down-regulating E-cadherin. However, FXYD5
expression was correlated with changes in cell morphology
in vitro, and with promotion of metastasis in vivo, in cell
lines and tumors that did not express any E-cadherin. These
findings suggest that E-cadherin dependence is not a general
phenomenon for all FXYD5 expressing tumor types (Shimamura,
2003; Shimada, 2004; Nishizawa et al., 2005; Tamura et al., 2005;
Lubarski et al., 2011).
A study, using a global gene expression analysis approach,
identified chemokine (C-C motif) ligand 2 (CCL2) as the
transcript most effected by silencing FXYD5 in MDA-MB-
231 breast cancer cells (Nam et al., 2006). Investigations in
animal model systems have recognized CCL2 as a mediator of
inflammation with pro-malignant activities. CCL2 was shown
to promote angiogenesis and act directly on the tumor cells to
increase their migratory and invasion-related properties (Soria
and Ben-Baruch, 2008). Correlation of FXYD5 expression with
CCL2 secretion was demonstrated in different cell lines (Nam
et al., 2006; Schüler et al., 2012). Furthermore, the ability of
FXYD5 to promote invasion of MDA MB231 cells in vivo was
inhibited by suppression of CCL2 (Nam et al., 2006).
In addition, more global, molecular changes were found to be
associated with FXYD5 overexpression in breast cancer model. It
was reported that FXYD5 expression results in enhancement of
NF-κB transcriptional activity (Nam et al., 2006). The presence
of FXYD5 was also accompanied by increased activation of AKT,
demonstrated by elevated abundance of phospho-AKT in breast
cancer tumors. Inhibition of AKT activity suppressed the ability
of FXYD5 to promote the activation of the NF-κB pathway.
Therefore, it was suggested that NF-κB activation might be a
downstream signaling of FXYD5-mediated AKT activation (Lee
et al., 2012).
Due to its ability to control cell proliferation and to suppress
apoptosis, the transcription factor NF-κB is broadly related
to carcinogenesis. Furthermore, the NF-κB pathway has been
associated with control of metastasis and angiogenesis (Bassères
and Baldwin, 2006; Karin, 2006). AKT is a serine/threonine
kinase that functions through its ability to phosphorylate a
number of key pro-oncogenic targets that promote cell growth
or inhibit apoptotic pathways (Hay, 2005; Manning and Cantley,
2007). The NF-κB transcription factor has been identified as a
target of the AKT signaling pathway (LoPiccolo et al., 2007).
In MDA-MB-231 cells, several hundred genes were reported
to be differentially expressed associated with FXYD5 silencing,
as determined by global gene expression analysis (Nam et al.,
2006). Since NF-κB is a transcription factor that is responsible
for a broad spectrum of cellular activities, it is possible that some
of the pathways described above are initiated as a consequence of
FXYD5-mediated NF-κB activation. However, it is not clear how
FXYD5 alters NF-κB or any of the affected proteins described
above. Since all the reported signaling events are modified at
the transcriptional level, it is also unclear whether the proposed
mechanisms are primary or secondary consequences of FXYD5
expression. Furthermore, direct interaction with FXYD5 has not
been established with any protein other than Na+/K+-ATPase.
FXYD5 OVER EXPRESSION ALTERS
EPITHELIAL MORPHOLOGY
Since FXYD5 normally resides in kidney epithelia, it was
logical to study the effects of its up-regulation in these cells.
FXYD5 over expression was first examined in the rodent M1
cell, on account of their ability to create and maintain tight
epithelial monolayer in vitro. In these cells, FXYD5 was shown
to induce dilation of tight and adherent junctions (TJ, AJ) and
promote expansion of interstitial spaces between the neighboring
cells. These morphological changes were observed by electron
microscopy and were further confirmed by re-distribution of
TJ and AJ markers (ZO-1, occludin, and β-catenin) in FXYD5
expressing monolayers (Figure 1). As a consequence, FXYD5
transfected M1 cells lost their tight epithelial integrity, measured
by reduced paracellular electrical resistance and increased trans-
cellular permeability to macro molecules (Lubarski et al., 2011).
The effects of FXYD5 were also studied at a single cell level.
It was found that the presence of FXYD5 results in impaired
adhesion of cells to the matrix, as observed by the reduced rate
of cell transformation from spherical to a flatter elongated shape,
with inhibited anterior-posterior polarity. This morphological
effect was seen consistently with several cell lines, and was
demonstrated both by silencing FXYD5 in cells that normally
express it (H1299, Panc-1), or transfecting FXYD5 into cells
that lack this protein (M1, HEK293). Cells expressing FXYD5
exhibit a less flattened elongated shape, demonstrated also by
a reduced number of focal adhesion points, as established by
differential immuno-staining of paxillin, the focal adhesion-
associated adaptor protein. Changes in focal adhesions were also
correlated with less organized actin fibers structure (Lubarski
et al., 2014).
Interestingly, there are some conflicting results concerning
effects of FXYD5 on motility parameters in different cell lines.
In some cell lines, the presence of FXYD5 evoked increased
cell migration, in agreement with previously published data (Ino
et al., 2002; Shimamura et al., 2004), whereas in others (M1 and
H1299) the opposite results were obtained. This discrepancy was
apparent for both single and collective cell movement. However,
changes in FXYD5-mediated adhesion were constant and more
robust finding that is not dependent on cell type (Lubarski et al.,
2014).
Looser cell–cell contacts and impaired cell-matrix association
could explain morphological changes associated with the role
of FXYD5 in the metastatic processes. However, since FXYD5
is expressed in a variety of normal epithelia the effects
described above might also be a component of its inherent
physiological role. Distribution of FXYD5 in “leaky” epithelia of
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FIGURE 1 | FXYD5 impairs cell–cell junction formation. (Upper) High
magnification of electron microscopy images of normal and FXYD5 transfected
M1 cell monolayer. Large expansions of interstitial spaces (IS) located just
under the TJ evoked by FXYD5 expression (asterisks). Bar = 200 nm. The EM
images were originally published in (Lubarski et al., 2011). (Lower)
Experimental mode of FXYD5 function. FXYD5 expression in M1 polarized
monolayer results in down regulation in membrane expression of TJ markers
ZO-1 and occludin. E-cadherin membrane localization remained intact, while
β-catenin, has been redistributed and appeared perpendicular to the
membrane plane. A reduced form of β glycosylation has been observed,
indicating an additional condition for promotion of “leaky” epithelia.
the gastro-intestinal tract could support this claim. An additional
possibility is that FXYD5 is transiently up-regulated under
conditions that require enhancement of paracellular permeability
as, for example, during nutrient absorbtion or for infiltration
of leukocytes during infection (Capaldo and Nusrat, 2009;
Turner, 2009). The mechanism underlying additional functions
of FXYD5 might also be explained as secondary effects following
the increased pump activity. However, the phenotypes observed
in vitro were apparent at very different pumping rates, arguing
against this notion (Lubarski et al., 2011).
FXYD5 ADDITIONAL EFFECTS MIGHT BE
MEDIATED BY ITS ASSOCIATION WITH
NA+/K+-ATPase
Another interesting effect of FXYD5 is the modification of
the glycosylation state of the β1-subunit of Na+/K+-ATPase.
FIGURE 2 | Expression of FXYD5 effects β1-Na+/K+-ATPase
glycosylation. Western blot of microsomes: left panel- Xenopus oocytes,
injected with αβ or αβ/FXYD5, middle panel- H1299 WT cells and shFXYD5
cells (shF5), right panel- M1 WT cell and FXYD5 transfected cells (+F5).
β1-Na+/K+-ATPase is represented by two bands, one for fully glycosylated
(f.g) and the other for core glycosylated (c.g.) form (marked with arrows).
FXYD5 expression reduces glycosylation level of fully glycosylated form
(asterisk). The figure was originally published in (Lubarski et al., 2007, 2011).
The Na+/K+-ATPase pump consists of the catalytic α and
structural β subunits. The classical role of β is to control
assembly and stability of alpha-beta heterodimers and plasma
membrane transport of sodiumpumps (McDonough et al., 1990).
The effect of FXYD5 on β1 glycosylation was noticed initially
in Xenopus oocytes, and has been observed consistently with
various mammalian expression systems that either normally
express FXYD5 or have been transfected with FXYD5 cDNA
(Figure 2; Lubarski et al., 2005, 2007, 2011). The phenomenon is
manifested as increased migration of the highly glycosylated β1
form in SDS-PAGE gels, when co-expressed with FXYD5, with
no change in its core unglycosylated protein. In general, this
phenomenon may imply ER retention of an immature protein
form. However, experiments determining the glycosylation state
of surface biotinylated β1 seem to argue against such a possibility.
Also, deglycosylation of β1 has no effect on the stability of the
αβ complex, as reflected by surface expression of the α subunit
in mammalian cells, and intact catalytic activity measured in
Xenopus oocytes (Lubarski et al., 2005, 2011).
Various FXYD5/FXYD4 chimeras, constructed for structure-
function studies, revealed that the presence of both trans-
membrane and extracellular domains of FXYD5 are required for
the reduced glycosylation of β1. Surprisingly, β deglycosylation
is the only experimentally observed effect attributable to the long
glycosylated extracellular portion of FXYD5, reported until now.
Interestingly, a similar effect was demonstrated for FXYD3, but
in this case the reduced glycosylation depended on the presence
of uncleaved signal peptide (Crambert et al., 2005).
FXYD5-dependent modification of β1 glycosylation might be
explained by a direct FXYD5-β interaction that may obstruct
addition of sialic acid residues at all sites, or interfere with
glycosylation at one or more positions. Although, according to
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the crystal structure (Toyoshima et al., 2011; Kanai et al., 2013)
the transmembrane helices of the β and FXYD subunits are
located at opposite sides of the α subunit, interactions between
their extracellular domains cannot be ruled out. Nevertheless, if
FXYD5-β interaction is possible, there is no certainty that it has
an effect on β processing. At least in the case of FXYD3, it was
demonstrated that the effect on glycosylation is not exclusive to
β and furthermore, is not dependent on direct interaction with
the Na+/K+-ATPase (Crambert et al., 2005). This evidence could
indicate that FXYD5- mediated modification of glycosylation is
not a direct effect, and might involve more global changes in
protein sorting or in glycosylation machinery, or alternatively,
that FXYD5 interacts with membrane proteins other than the
Na+/K+-ATPase.
The functional significance of the above behavior may
explain additional functions attributed to the β1 subunit. For
example, several studies have provided evidence that the β1
subunit of Na+/K+-ATPase has a role as an adhesion molecule.
Transcellular β1–β1 interactions have been shown to be involved
in preservation and regulation of epithelial junctions, and the
sugars moieties of the β extracellular domain were found to
be important for maintaining β mediated cell–cell contacts
(for a review see Vagin et al., 2012). Hence, FXYD5-mediated
interference in β glycan structure, either direct or indirect, may
result in “looser” junctions, characteristic of FXYD5 expressing
cells.
The effect of FXYD5 on cell-matrix adhesion was also found
to be mediated through its interaction with Na+/K+-ATPase.
Specifically, two point mutations in the transmembrane segment
demonstrated that association of FXYD5 with the pump is
directly related with changes in cell morphology (Lubarski
et al., 2014). Similar conclusions were drawn from Ser163Asp
mutation. The negative charge at the mutated Ser163Asp residue,
that mimics phosphorylation, has been proposed to regulate
FXYD5/Na+/K+-ATPase association and this interaction has
been correlated with modulation of collective cell movement
in airway epithelial cells (Miller and Davis, 2008b). However,
in contrast to the transmembrane mutations, the Ser163Asp
mutation also interfered with plasma membrane localization of
FXYD5.
KEY CONCEPTS AND FUTURE RESEARCH
PERSPECTIVES
FXYD5 is an establishedmodulatory subunit of Na+/K+-ATPase,
expressed in a variety of epithelial cells. Nevertheless, the function
of its unique extracellular structural domain still remains elusive
(Lubarski et al., 2005, 2007; Miller and Davis, 2008a). FXYD5
is up-regulated under several pathological conditions and its
increased expression and differentially-modified molecular form
in various malignancies pointed to possible functions in addition
to kinetic modulation of Na+/K+-ATPase activity (Ino et al.,
2002; Nam et al., 2007; Igwe et al., 2009; Boon et al., 2012).
FXYD5-mediated alterations in cell morphology in vitro, and
substantial transcriptional modification cannot be explained
only by changes in Na+/K+-ATPase activity. The proposed
molecular mechanisms underlying its effects in adhesion,
motility, paracellular permeability, and metastatic progression
vary between different cell types. The only consistently observed
interaction of FXYD5 is with Na+/K+-ATPase. In addition
to increasing the Na+/K+-ATPase pumping rate, FXYD5 has
been shown to modify the glycosylation state of the β1 subunit
(Lubarski et al., 2005, 2007, 2011). In parallel, a role of Na+/K+-
ATPase as an adhesion molecule and the contribution of the β1
subunit to adherent junction formation have been established
(Vagin et al., 2012). Therefore, a correlation between these
processes has been proposed.
For the future a major focus should be on the physiological
relevance underlying the effect of FXYD5 on Na+/K+-ATPase
activity. The nature of FXYD5-mediated β1 carbohydrate
modifications is a major question. This could call for a search for
more global changes, since it appears obvious, that glycosylation
of more than one protein is affected by FXYD5. In support of this
notion, a role of another FXYD protein that shares this feature,
FXYD3, has also been suspected in carcinogenesis (Maxwell et al.,
2003). Altered glycosylation is a universal feature of cancer cells
and it may explain several of FXYD5-induced morphological
changes (Varki et al., 2009).
Finally, a most intriguing line of research could be to search
for the trigger that activates transformation or modification
of FXYD5 from its role in normal tissue to that in the
malignant state. The reported up-regulation of FXYD5 in
pathological conditions that require stabilization of the pump
activity may shed light on the initial event that elicits malignant
transformation.
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